Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia

Blood

Volumn 121, Issue 3, 2013, Pages 476-484

  Waldmann, Thomas A ^a   Conlon, Kevin C ^a   Stewart, Donn M ^a   Worthy, Tat Yana A ^a   Janik, John E ^a   Fleisher, Thomas A ^b   Albert, Paul S ^c   Figg, William D ^a   Spencer, Shawn D ^d   Raffeld, Mark ^a   Decker, Jean R ^a   Goldman, Carolyn K ^a   Bryant, Bonita R ^a   Petrus, Michael N ^a   Creekmore, Stephen P ^e   Morris, John C ^a,f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d SAIC FREDERICK INC   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR GAMMA; MESSENGER RNA; MIK BETA 1 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE MYOSITIS; BONE MARROW; CLINICAL ARTICLE; DRUG DISTRIBUTION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS; EYE; FEMALE; HUMAN; IMMUNOGENICITY; KIDNEY; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LARGE INTESTINE; LIVER; LUNG; LYMPH NODE; MALE; MAXIMUM PLASMA CONCENTRATION; MYOSITIS; OVARY; PANCREAS; PARATHYROID GLAND; PAROTID GLAND; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE; SIDE EFFECT; SKELETAL MUSCLE; SKIN; SMALL INTESTINE; SPINAL CORD; SPLEEN; STOMACH; T LYMPHOCYTE; TESTIS; TONSIL; TREATMENT RESPONSE; UTERUS;

EID: 84872482913     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-450585     Document Type: Article

References (49)

1. Bamford RN, Grant AJ, Burton JD, et al. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A. 1994; 91(11): 4940-4944.
2. Grabstein KH, Eisenman J, Shanebeck K, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 1994; 264(5161): 965-968. (Pubitemid 24196167)
3. Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol. 1999; 17: 19-49. (Pubitemid 29241118)
4. Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity. 2001; 14(5): 105-110. (Pubitemid 32206513)
5. Marks-Konczalik J, Dubois S, Losi JM, et al. IL-2 induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A. 2000; 97(21): 11445-11450.
6. Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memoryphenotype CD8+T cells in vivo by IL-15. Immunity. 1998; 8(5): 591-599. (Pubitemid 28264750)
7. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001; 97(1): 14-32. (Pubitemid 32061238)
8. Giri JG, Kumaki S, Ahdieh M, et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J. 1995; 14(15): 3654-3663.
9. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15R alpha recycles and presents IL-15 in trans to neighboring cells. Immunity. 2002; 17(5): 537-547. (Pubitemid 35351500)
10. Lodolce JP, Boone DL, Chai S, et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity. 1998; 9(5): 669-676. (Pubitemid 28557595)
11. Cooper MA, Bush JE, Fehniger TA, et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood. 2002; 100: (10)3633-3638. (Pubitemid 35303933)
12. Koka R, Burkett P, Chien M, Chai S, Boone DL, Ma A. Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells. J Immunol. 2004; 173(6): 3594-3598. (Pubitemid 39280717)
13. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006; 6(8): 595-601. (Pubitemid 44134092)
14. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T celldependent regulation of tumor necrosis factoralpha production in rheumatoid arthritis. Nat Med. 1997; 3(2): 189-195. (Pubitemid 27064704)
15. Blanco-Jerez C, Plaza JF, Masjuan J, Orensanz LM, Alvarez-Cermeno JC. Increased levels of IL-15 mRNA in relapsing-remitting multiple sclerosis attacks. J Neuroimmunol. 2002; 128(1-2): 90-94. (Pubitemid 34722368)
16. Ohta N, Hiroi T, Kweon MN, et al. IL-15-dependent activation-induced cell death-resistant Th1 type CD8 alpha beta+ NK1.1+ T cells for the development of small intestinal inflammation. J Immunol. 2002; 169(1): 460-468. (Pubitemid 34686168)
17. Benahmed M, Meresse B, Arnulf B, et al. Inhibition of TGF-beta signaling by IL-15: a new role for IL-15 in the loss of immune homeostasis in celiac disease. Gastroenterology. 2007; 132(3): 994-1008. (Pubitemid 46440858)
18. Meresse B, Curran SA, Ciszewski C, et al. Reprogramming of CTLs into natural killer-like cells in celiac disease. J Exp Med. 2006; 203(5): 1343-1355. (Pubitemid 43736602)
19. Kuczyński S, Winiarska H, Abramczyk M, Szczawinska K, Wierusz-Wysocka B, Dworacka M. IL-15 is elevated in serum patients with type 1 diabetes mellitus. Diabetes Res Clin Pract. 2005; 69(3): 231-236. (Pubitemid 41140101)
20. Azimi N, Nagai M, Jacobson S, Waldmann TA. IL-15 plays a major role in the persistence of Taxspecific CD8 cells in HAM/TSP patients. Proc Natl Acad Sci U S A. 2001; 98(14): 14559-14564. (Pubitemid 33121431)
21. Kim YS, Maslinski W, Zheng XX, et al. Targeting the IL-15 receptor with an antagonist IL-15 mutant/ Fcgamma2a protein blocks delayed-type hypersensitivity. J Immunol. 1998; 160(12): 5742-5748. (Pubitemid 28298030)
22. Baslund B, Tvede N, Danneskiold-Samsoe B, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum. 2005; 52(9): 2686-2692. (Pubitemid 41369096)
23. Morris JC, Janik JE, White JD, et al. Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia. Proc Natl Acad Sci U S A. 2006; 103(2): 401-406. (Pubitemid 43122413)
24. Hakimi J, Ha VC, Lin P, et al. Humanized Mik- Beta-1, a humanized antibody to the IL-2 receptor beta-chain that acts synergistically with humanized anti-Tac. J Immunol. 1993; 151(2): 1075-1085. (Pubitemid 23215772)
25. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A. 1989; 86(24): 10029-10033. (Pubitemid 20030769)
26. Tinubu SA, Hakimi J, Kondas JA, et al. Humanized antibody directed to the IL-2 receptor γ -chain prolongs primate cardiac allograft survival. J Immunol. 1994; 153(9): 4330-4338. (Pubitemid 24322600)
27. Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood. 1993; 82(1): 1-14. (Pubitemid 23188739)
28. Zhang R, Shah MV, Yang J, et al. Network model of survival signaling in large granular lymphocytes leukemia. Proc Natl Acad Sci U S A. 2008; 105(42): 16308-16313.
29. Zambello R, Facco M, Trentin L, et al. Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Blood. 1997; 89(1): 201-211. (Pubitemid 26428194)
30. Chen J, Petrus M, Bamford R, et al. Increased serum soluble IL-15R alpha levels in T-cell large granular lymphocyte leukemia. Blood. 2012; 119(1): 137-143.
31. Tsudo M, Kitamura F, Miyasaka M. Characterization of the interleukin-2 receptor beta-chain using 3 distinct monoclonal antibodies. Proc Natl Acad Sci U S A. 1989; 86(6): 1982-1986. (Pubitemid 19087052)
32. Eberle FC, Song JY, Xi L, et al. Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma. Am J Surg Pathol. 2012; 36(5): 716-725.
33. Schlossman SF, Boumsell L, Gilks W, et al. Leukocyte typing V: white cell differentiation antigens. Proceedings of the Fifth International Workshop and Conference held in Boston U S A. Vol 1. Oxford, United Kingdom, Oxford University Press 1995: 184.
34. Keenan CM, Vidal JD. Standard morphologic evaluation of the heart in the laboratory dog and monkey. Toxicol Pathol. 2006; 34(1): 67-74.
35. Chamanza R, Marxfeld HA, Blanco Al Naylor SW, Bradley AE. Incidences and range of spontaneous findings in control cynomolgus monkeys (Macaca fascicularis) used in toxicity studies. Toxicol Pathol. 2010; 38(4): 642-657.
36. Zabka TS, Irwin M, Albassam MA. Spontaneous cardiomyopathy in cynomolgus macaques (Macaca fascicularis). Toxicol Pathol. 2009; 37(6): 814-818.
37. Vidal JD, Drobatz LS, Holliday DF, Geiger LE, Thomas HC. Spontaneous findings in the heart of Mauritian-origin cynomolgus macaques (Macaca fascicularis). Toxicol Pathol. 2010; 38 (2): 297-302.
38. Hori T, Uchiyama T, Tsudo M, et al. Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/ lymphoma virus. Blood. 1987; 70(4): 1069-1072. (Pubitemid 18022384)
39. Chen J, Petrus M, Bryant BR, et al. Autocrine/ paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia. Blood. 2010; 116 (26): 5948-5956.
40. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012; 366(20): 1905-1913.
41. Sakai JA, Nagai M, Brennan MB, Mora CA and Jacobson S. In vitro spontaneous lymphoproliferation in patients with human T-cell lymphotrophic virus type I-associated neurological disease predominant expansion of CD8+ T cells. Blood. 2001; 98(5): 1506-1511.
42. Itoyama Y, Minato S, Kira J, et al. Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy. Neurology. 1988; 38(8): 1302-1307.
43. Lunardi-Iskandar Y, Gessain A, Lam VH, Gallo RC. Abnormal in vitro proliferation and differentiation of T cell colony-forming cells in patients with tropical spastic paraparesis/human T lymphocyte virus type I (HTLV-I)-associated myeloencephalopathy and healthy HTLV-I carriers. J Exp Med. 1993; 177(3): 741-750. (Pubitemid 23104285)
44. Mariner JM, Lantz V, Waldmann TA, Azimi N. Human T-cell lymphotropic virus type I Tax protein activates interleukin-15R alpha gene expression through an NF-kappa B site. J Immunol. 2001; 166(4): 2602-2609. (Pubitemid 32173498)
45. Jabri B, Sollid LM. Mechanisms of disease: Immunopathogenesis of celiac disease. Nat Clin Pract Gastroenterol Hepatol. 2006; 3(9): 516-525. (Pubitemid 44322763)
46. Meresse B, Chen Z, Ciszewski C, et al. Coordinated induction by IL-15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity. 2004; 21(3): 357-366. (Pubitemid 39208337)
47. Mention J-J, Ben Ahmed M, Bègue B, et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology. 2003; 125(3): 730-745. (Pubitemid 37070691)
48. Di Sabatino A, Ciccocioppo R, Cupelli F, et al. Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut. 2006; 55(4): 469-477.
49. Yokoyama S, Watanabe N, Sato N, Perera PY, Filkoski L. Tanaka T, Miyasaka M, Waldmann TA, Hiroi T, Perera LP. Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. Proc Natl Acad Sci U S A. 2009; 106(37): 15849-15854.